|Full HTA Assessment
|For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not Recommended
We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.